Advertisement

Internal and Emergency Medicine

, Volume 8, Issue 1, pp 13–22 | Cite as

Herbal hepatotoxicity: a hidden epidemic

  • Anna Licata
  • Fabio Salvatore Macaluso
  • Antonio Craxì
IM - REVIEW

Abstract

Complementary and alternative therapies, including herbal products, have become increasingly popular in the general population and among patients and physicians. Regulations and pharmacovigilance regarding herbal drugs are still incomplete and need to be improved. In fact, herbals are commonly marketed on the Internet, and in many countries they are sold as food supplements, which are beyond the control of drug regulatory agencies. In Europe and the U.S., reports of hepatotoxicity from these products, including those advertised for liver diseases, are accumulating. Many herbal drugs are also commonly used in children, and in women during pregnancy and lactation, because they are believed to be “natural” and, therefore, “harmless.” One emerging problem is people preferring herbal-based slimming aids to conventional dietary and physical activity. In Italy, the use of non-conventional therapies has been reported for 13.6 % of the population, and 3.7 % freely use herbal drugs, unaware of the risks associated with a potential interaction with prescription drugs. In our review, we discuss the problem of the lack of standardization of herbal drugs, the lack of randomized clinical trials regarding the majority of these products, the unawareness of risks by the patients who buy and use them, and, further, the problem of underreporting. For the most commonly used herbal products and slimming aids, we describe their potential hepatotoxicity mechanisms, the causality assessment necessary for a correct diagnosis, and the clinical patterns for which these products seem to be responsible.

Keywords

Herbal remedies (HRs) Dietary supplement (DS) Slimming aids Hepatotoxicity Prevention 

Notes

Conflict of interest

None.

References

  1. 1.
    Tyler VE, Foster S (1999) Tyler’s Honest Herbal; The Physicians’ Desk Reference for Herbal Medicines (annual)Google Scholar
  2. 2.
    Goldman P (2001) Herbal medicine today and the roots of modern pathology. Ann Intern Med 135:594–600PubMedGoogle Scholar
  3. 3.
    Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39:293–304PubMedCrossRefGoogle Scholar
  4. 4.
    Calapai G (2008) European legislation on herbal medicines: a look into the future. Drug Saf 31:428–431PubMedCrossRefGoogle Scholar
  5. 5.
    Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro P, Calapai G, Firenzuoli F et al (2008) Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf 17:626–635PubMedCrossRefGoogle Scholar
  6. 6.
    Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA et al (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135:262–268PubMedGoogle Scholar
  7. 7.
    Navarro V (2009) Herbal and dietary supplement hepatotoxicity. Sem Liv Dis 29:3733–3782CrossRefGoogle Scholar
  8. 8.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRefGoogle Scholar
  9. 9.
    Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323–1330PubMedCrossRefGoogle Scholar
  10. 10.
    Maria VA, Victorino RM (1997) Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 26:664–669PubMedCrossRefGoogle Scholar
  11. 11.
    Watanabe M, Shibuya A (2004) Validity study of a new diagnostic scale for drug-induced liver injury in Japan—comparison with two previous scales. Hepatol Res 30:148–154PubMedCrossRefGoogle Scholar
  12. 12.
    Strader DB, Bacon BR, Lindsay KL, La Breque DR, Morgan T, Wright EC et al (2002) Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 97:2391–2397PubMedCrossRefGoogle Scholar
  13. 13.
    Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRefGoogle Scholar
  14. 14.
    Stickel F, Patsenker E, Schuppan D (2005) Herbal hepatotoxicity. J Hepatol 43:901–910PubMedCrossRefGoogle Scholar
  15. 15.
    National Institute of Statistic (2007) Le terapie non convenzionali in Italia. ISTAT, RomeGoogle Scholar
  16. 16.
    Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R et al (2011) Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health. Eur J Clin Pharmacol 67:215–224PubMedCrossRefGoogle Scholar
  17. 17.
    Menniti-Ippolito F, Forcella E, Bologna E, Gargiulo L, Traversa G, Raschetti R (2002) Use of unconventional medicine in children in Italy. Eur J Pediatr 161:690PubMedCrossRefGoogle Scholar
  18. 18.
    Zaffani S, Cuzzolin L, Benoni G (2006) Herbal products: behaviours and beliefs among Italian women. Pharmacoepidemiol Drug Saf 15:354–359PubMedCrossRefGoogle Scholar
  19. 19.
    Gardner DR, Panter KE, James LF, Stegelmeier BL (1998) Abortifacient effects of lodgepole pine (Pinus contorta) and common juniper (Juniperus communis) on cattle. Vet Hum Toxicol 40:260–263PubMedGoogle Scholar
  20. 20.
    Bilgi N, Bell K, Ananthakrishnan AN, Atallah E (2010) Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 44:926–928PubMedCrossRefGoogle Scholar
  21. 21.
    Kocaman O, Hulagu S, Senturk O (2008) Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis. Eur J Intern Med 19:148PubMedCrossRefGoogle Scholar
  22. 22.
    Lucenteforte E, Gallo E, Pugi A, Giommoni F, Paoletti A, Vietri M et al. (2011) Complementary and alternative drugs use among preoperative patients: a cross-sectional study in Italy. Evid Based Complement Alternat Med. doi: 10.1155/2012/527238
  23. 23.
    Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB et al (2008) Safety of green tea extracts. A systematic review by the US pharmacopeia. Drug Saf 31:469–484PubMedCrossRefGoogle Scholar
  24. 24.
    Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C et al (2009) Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65:331–341PubMedCrossRefGoogle Scholar
  25. 25.
    Stickel F, Kessebohm K, Weimann R, Seitz HK (2011) Review of liver injury associated with dietary supplements. Liver Int 31:595–605PubMedCrossRefGoogle Scholar
  26. 26.
    Galati G, Lin A, Sultan AM, O’Brien PJ (2006) Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 40:570–580PubMedCrossRefGoogle Scholar
  27. 27.
    Jin X, Zheng RH, Li YM (2008) Green tea consumption and liver disease: a systematic review. Liver Int 28:990–996PubMedCrossRefGoogle Scholar
  28. 28.
    Yang CS, Lambert JD, Ju J, Lu G, Sang S (2007) Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 224:265–273PubMedCrossRefGoogle Scholar
  29. 29.
    Weston CFM, Cooper BT, Davies JD, Levine DF (1987) Veno-occlusive disease of the liver secondary to ingestion of comfrey. BMJ 295:183PubMedCrossRefGoogle Scholar
  30. 30.
    Stickel F, Seitz HK (2000) The efficacy and safety of comfrey. Pub Health Nutr 3:501–508Google Scholar
  31. 31.
    Kassler WJ, Blanc P, Greenblatt R (1991) The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med 151:2281–2288PubMedCrossRefGoogle Scholar
  32. 32.
    Sheikh NM, Philen RM, Love LA (1997) Chaparral-associated hepatotoxicity. Arch Intern Med 157:913–919PubMedCrossRefGoogle Scholar
  33. 33.
    Agarwal R, Wang ZY, Bik DP, Mukhtar H (1991) Nordihydroguaiaretic acid, an inhibitor of lipoxygenase, also inhibits cytochrome P-450-mediated monooxygenase activity in rat epidermal and hepatic microsomes. Drug Metab Dispos 19:620–624PubMedGoogle Scholar
  34. 34.
    Stevinson C, Ernst E (2000) Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 1:91–99PubMedCrossRefGoogle Scholar
  35. 35.
    Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA (2004) In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 7:265–273PubMedGoogle Scholar
  36. 36.
    Cohen DL, Del Toro Y (2008) A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 42:961–962PubMedCrossRefGoogle Scholar
  37. 37.
    Vassiliadis T, Anagnostis P, Patsiaoura K, Giouleme O, Katsinelos P, Mpoumponaris A et al (2009) Valeriana hepatotoxicity. Sleep Med 10:935PubMedCrossRefGoogle Scholar
  38. 38.
    Piccolo P, Gentile S, Alegiani F, Angelico M (2009) Severe drug induced acute hepatitis associated with use of St John’s wort (Hypericum perforatum) during treatment with pegylated interferon α. BMJ Case Rep. doi: 10.1136/bcr.08.2008.0761
  39. 39.
    Etogo-Asse F, Boemer F, Sempoux C, Geubel A (2008) Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John’s wort). Case of drug interaction? Acta Gastroenterol Belg 71:36–38PubMedGoogle Scholar
  40. 40.
    Stedman C (2002) Herbal hepatotoxicity. Semin Liver Dis 22:195–206PubMedCrossRefGoogle Scholar
  41. 41.
    Woolf GM, Petrovic LM, Roiter SE, Wainwright S, Villamil FG, Katkov WN et al (1994) Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 121:729–735PubMedGoogle Scholar
  42. 42.
    Picciotto A, Campo N, Brizzolara R, Giusto R, Guido G, Sinelli N et al (1998) Chronic hepatitis induced by Jin Bu Huan. J Hepatol 28:165–167PubMedCrossRefGoogle Scholar
  43. 43.
    World Health Organization (2007) Assessments of the risk of hepatotoxicity with kava products. WHO Document Production Services, GenevaGoogle Scholar
  44. 44.
    Teschke R, Schwarzenboeck A, Hennermann KH (2008) Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 20:1182–1193PubMedCrossRefGoogle Scholar
  45. 45.
    Teschke R, Schwarzenboeck A, Akinci A (2008) Kava hepatotoxicity: a European view. N Z Med J 121:90–98PubMedGoogle Scholar
  46. 46.
    Teschke R (2010) Kava hepatotoxicity—a clinical review. Ann Hepatol 9:251–265PubMedGoogle Scholar
  47. 47.
    Teschke R (2010) Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 30:1270–1279PubMedCrossRefGoogle Scholar
  48. 48.
    Colombo ML, Bosisio E (1996) Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res 33:127–134PubMedCrossRefGoogle Scholar
  49. 49.
    Moro PA, Cassetti F, Giugliano G, Falce MT, Mozzanti G, Menniti-Ippolito F et al (2009) Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 124:328–332PubMedCrossRefGoogle Scholar
  50. 50.
    Greving I, Meister V, Monnerjahn C, Muller KM, May B (1998) Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Safety 7:S66–S69CrossRefGoogle Scholar
  51. 51.
    Larrey D (1997) Hepatotoxicity of herbal remedies. J Hepatol 26:47–51PubMedCrossRefGoogle Scholar
  52. 52.
    Obatomi DK, Brant S, Anthony-Pillai V, Bach PH (1998) Toxicity of atractylosides in precicion-cut rat and porcine renal and hepatic tissue slices. Toxicol Appl Pharmacol 148:35–45PubMedCrossRefGoogle Scholar
  53. 53.
    Dunbar K, Solga SF (2007) Black cohosh, safety, and public awareness. Liver Int 27:1017–1018PubMedCrossRefGoogle Scholar
  54. 54.
    Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R et al (2008) United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15:628–638PubMedCrossRefGoogle Scholar
  55. 55.
    EMEA. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www.emea.europa.eu/pdfs/human/hmpc/
  56. 56.
    Teschke R (2010) Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 17:426–440PubMedCrossRefGoogle Scholar
  57. 57.
    Firenzuoli F, Gori L, di Sarsina PR (2011) Black cohosh hepatic safety: follow-up of 107 patients consuming a special Cimicifuga racemosa rhizome herbal extract and review of literature. Evid Based Complement Alternat Med. doi: 10.1093/ecam/nen009
  58. 58.
    US Food and Drug Administration. Warning on Hydroxycut products. Available at http://www.fda.gov
  59. 59.
    Dara L, Hewett J, Lim JK (2008) Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 14:6999–7004PubMedCrossRefGoogle Scholar
  60. 60.
    Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA et al (2010) Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenterol 105:1561–1566PubMedCrossRefGoogle Scholar
  61. 61.
    Lobb A (2009) Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol 15:1786–1787PubMedCrossRefGoogle Scholar
  62. 62.
    Nadir A, Agrawal S, King P, King PD, Marshall JB (1996) Acute hepatitis associated with the use of a chinese herbal product, Ma huang. Am J Gastoenterol 91:1436–1438Google Scholar
  63. 63.
    Borum ML (2001) Fulminant exacerbation of autoimmune hepatitis after the use of Ma huang. Am J Gastroenterol 96:1654–1655PubMedCrossRefGoogle Scholar
  64. 64.
    Skoulidis F, Alexander GJ, Davies SE (2005) Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 17:581–584PubMedCrossRefGoogle Scholar
  65. 65.
    Bajaj J, Knox JF, Komorowski R, Saeian K (2003) The irony of herbal hepatitis. Ma-huang induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig Dis Sci 48:1925–1928PubMedCrossRefGoogle Scholar
  66. 66.
    Favreau JT, Ryu ML, Braunstein G, Orshansky G, Park SS, Coody GL et al (2002) Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136:590–595PubMedGoogle Scholar
  67. 67.
    Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M et al (2004) Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 99:950–952PubMedCrossRefGoogle Scholar
  68. 68.
    Sanchez W, Maple JT, Burgart LJ, Kamath PS (2006) Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 81:541–544PubMedCrossRefGoogle Scholar
  69. 69.
    Han D, Matsumaru K, Rettori D, Kaplowitz N (2004) Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 67:439–451PubMedCrossRefGoogle Scholar
  70. 70.
    Gori L, Galluzzi P, Mascherini V, Gallo E, Lapi F et al (2011) Two contemporary cases of hepatitis associated with Teucrium chamaedrys L. Decoction use. Case reports and review of literature. Basic Clin Pharmacol Toxicol 109:521–526PubMedCrossRefGoogle Scholar
  71. 71.
    Mazokopakis E, Lazaridou S, Tzardi M, Mixaki J, Diamantis I et al (2004) Acute cholestatic hepatitis caused by Teucrium polium L. Phytomedicine 11:83–84PubMedCrossRefGoogle Scholar
  72. 72.
    Lekehal M, Pessayre D, Lereau JM, Moulis C, Fouraste I, Fau D (1996) Hepatotoxicity of the herbal medicine, germander, metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 24:212–218PubMedCrossRefGoogle Scholar
  73. 73.
    Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E et al (2007) Association between consumption of Herbalifes nutritional supplements and acute hepatotoxicity. J Hepatol 47:514–520PubMedCrossRefGoogle Scholar
  74. 74.
    Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J et al (2007) Herbal does not mean innocuous: 10 cases of severe hepatotoxicity associated with dietary supplements from Herbalifes products. J Hepatol 47:521–526PubMedCrossRefGoogle Scholar
  75. 75.
    Duque JM, Ferreiro J, Salgueiro E, Manso G (2007) Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin (Barc) 128:238–239CrossRefGoogle Scholar
  76. 76.
    Chao S, Anders M, Turbay M, Olaiz E, Mc Cormack L, Mastai R (2008) Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol Latinoam 38:274–277PubMedGoogle Scholar
  77. 77.
    Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL (2009) Severe hepatotoxicity following ingestion of Herbalifes nutritional supplements contaminated with Bacillus subtilis. J Hepatol 50:111–117PubMedCrossRefGoogle Scholar
  78. 78.
    Johannsson M, Ormarsdottir S, Olafsson S (2010) Hepatotoxicity associated with the use of Herbalife. Laeknabladid 96:167–172PubMedGoogle Scholar
  79. 79.
    Lin G, Wang JY, Li N, Gao H, Ji Y, Zhang F et al (2010) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54:666–673PubMedCrossRefGoogle Scholar
  80. 80.
    Larrey D, Faure S (2011) Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol 54:599–601PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2012

Authors and Affiliations

  • Anna Licata
    • 1
  • Fabio Salvatore Macaluso
    • 1
  • Antonio Craxì
    • 1
  1. 1.Sezione di Gastroenterologia ed Epatologia, DiBiMISUniversity of PalermoPalermoItaly

Personalised recommendations